论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors He S, Liu Q, Li H, Tian F, Chen S, Weng J
Received 19 December 2017
Accepted for publication 9 January 2018
Published 5 March 2018 Volume 2018:14 Pages 475—482
DOI https://doi.org/10.2147/TCRM.S160298
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Hoa Le
Peer reviewer comments 2
Editor who approved publication: Professor Deyun Wang
Background: The prevention of
cardiac surgery-associated acute kidney injury (CSA-AKI) by statins remains
controversial. Therefore, the present meta-analysis including randomized
controlled trials (RCTs) was performed to assess the effect of perioperative
statin on CSA-AKI.
Methods: Two reviewers independently searched for RCTs
about perioperative statin for prevention of CSA-AKI. The primary endpoint was
CSA-AKI. Relative risk was calculated between statin and placebo for preventing
CSA-AKI using the random-effect model or fixed-effect model according to
different heterogeneity.
Results: Eight RCTs met inclusion criteria, including
five studies with atorvastatin, two with rosuvastatin, and one with
simvastatin. There were 1,603 patients receiving statin treatment and 1,601
with placebo. Perioperative statin therapy did not reduce the incidence of
CSA-AKI (relative risk =1.17, 95% CI: 0.98–1.39, p =0.076). Furthermore,
perioperative statin increased the risk of CSA-AKI in the subgroup analysis
with clear definition of CSA-AKI and those with JADAD score >3.
Perioperative rosuvastatin produced slightly significantly higher risk of AKI
than atorvastatin therapy (p =0.070). Statin
intervention both pre and post surgery slightly increased the risk of CSA-AKI
versus preoperative statin therapy alone (p =0.040).
Conclusions: Perioperative statin therapy might increase the
risk of CSA-AKI after cardiac surgery.
Keywords: statin,
perioperative, acute kidney injury, cardiac surgery, meta-analysis